Elutia Inc. (ELUT)
NASDAQ: ELUT · Real-Time Price · USD
0.9049
+0.0149 (1.67%)
At close: Oct 13, 2025, 4:00 PM EDT
0.8969
-0.0080 (-0.88%)
Pre-market: Oct 14, 2025, 5:56 AM EDT
Elutia Revenue
Elutia had revenue of $6.26M in the quarter ending June 30, 2025, a decrease of -0.45%. This brings the company's revenue in the last twelve months to $23.68M, down -5.22% year-over-year. In the year 2024, Elutia had annual revenue of $24.38M, down -1.50%.
Revenue (ttm)
$23.68M
Revenue Growth
-5.22%
P/S Ratio
1.41
Revenue / Employee
$464,373
Employees
51
Market Cap
38.36M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 24.38M | -370.00K | -1.50% |
Dec 31, 2023 | 24.75M | 896.00K | 3.76% |
Dec 31, 2022 | 23.85M | -23.54M | -49.68% |
Dec 31, 2021 | 47.39M | 4.71M | 11.03% |
Dec 31, 2020 | 42.68M | -219.00K | -0.51% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ELUT News
- 3 days ago - Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors - GlobeNewsWire
- 12 days ago - Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million - GlobeNewsWire
- 27 days ago - Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation - GlobeNewsWire
- 4 weeks ago - Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million - GlobeNewsWire
- 5 weeks ago - Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange - GlobeNewsWire
- 6 weeks ago - Elutia to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Elutia Inc. (ELUT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption - GlobeNewsWire